Evolus, Inc. (EOLS) AI Stock Analysis

Evolus, Inc., founded in 2012 and headquartered in Newport Beach, California, is a performance beauty company providing medical aesthetic solutions to healthcare professionals and their patients. Its primary product is Jeuveau, a proprietary 900-kilodalton purified botulinum toxin type A formulation. Jeuveau is approved for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company focuses on research, development, and regulatory compliance to supply healthcare providers with non-invasive aesthetic treatments for facial rejuvenation across the United States.

Between FY2021 and FY2025, Evolus expanded annual revenue from $99.7M to $297.2M, reflecting a 5-year revenue CAGR of 39.4% from FY2020 to FY2025. Gross margin stood at 64.9% in FY2025, compared to 56.3% in FY2021. However, operating margin remained negative at -12.7% in FY2025, alongside a net loss of -$51.6M and EPS of -$0.62. For the trailing twelve months ended June 30, 2026, revenue was $316.5M with an operating margin of -5.2% and EPS of -$0.53, while latest quarterly revenue grew 21.2% year-over-year.

As of June 30, 2026, Evolus held $45.2M in cash and short-term investments against $164.8M in total debt, yielding net debt of $119.6M. Total assets were $248.0M and the current ratio was 1.70. Shareholders' equity was negative at -$30.9M. In FY2025, operating cash flow was -$42.3M, free cash flow was -$50.7M, and capital expenditures were $8.5M. The company's share count increased 18.6% over five years.

At a share price of $7.10, Evolus has a market cap of $469.0M and an enterprise value of $648.0M. Its price-to-sales ratio is 1.5x, below the 4.1x median of its US-listed Healthcare peers. The forward P/E ratio is 17.0x compared to the peer median of 17.3x, while EV to revenue is 2.0x. Over the past year, EOLS generated a return of 12.7%, trailing the S&P 500 (SPY) return of 16.8%. Over five years, the stock returned -7.4% against 83.0% for the S&P 500.

Wall Street coverage includes 4 Strong Buy, 1 Buy, and 1 Hold rating, with no Sell recommendations. The mean price target is $15.00, representing 111.3% upside from the last close of $7.10. For the fiscal year ending December 31, 2026, analysts estimate revenue of $334.2M and EPS of -$0.05. For FY2027, 4 analysts estimate revenue of $392.2M and positive EPS of $0.29. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 4, 2026.

This page is an AI-written research summary of Evolus, Inc. (EOLS). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: EOLS income statement, EOLS balance sheet, EOLS key metrics, EOLS analyst forecast, EOLS chart. See the EOLS stock overview for the latest quote and news.